These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 30017658)

  • 1. Therapy-related acute myeloid leukemia developing 14 years after allogeneic hematopoietic stem cell transplantation, from a persistent R882H-DNMT3A mutated clone of patient origin.
    Martín I; Navarro B; Villamón E; Solano C; Serrano A; Calabuig M; Amat P; Domingo F; Abellán R; García F; Olivares MD; Chaves FJ; Tormo M; Hernández-Boluda JC
    Exp Mol Pathol; 2018 Aug; 105(1):139-143. PubMed ID: 30017658
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quantitative detection of DNMT3A R882H mutation in acute myeloid leukemia.
    Berenstein R; Blau IW; Suckert N; Baldus C; Pezzutto A; Dörken B; Blau O
    J Exp Clin Cancer Res; 2015 May; 34(1):55. PubMed ID: 25994761
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Persistent DNMT3A mutation burden in DNMT3A mutated adult cytogenetically normal acute myeloid leukemia patients in long-term remission.
    Sun Y; Shen H; Xu T; Yang Z; Qiu H; Sun A; Chen S; Wu D; Xu Y
    Leuk Res; 2016 Oct; 49():102-7. PubMed ID: 27626217
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical Utility of Next-Generation Sequencing for Oncogenic Mutations in Patients with Acute Myeloid Leukemia Undergoing Allogeneic Stem Cell Transplantation.
    Luskin MR; Carroll M; Lieberman D; Morrissette JJD; Zhao J; Crisalli L; Roth DB; Luger SM; Porter DL; Reshef R
    Biol Blood Marrow Transplant; 2016 Nov; 22(11):1961-1967. PubMed ID: 27478011
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Allogeneic hematopoietic stem cell transplantation could improve survival of cytogenetically normal adult acute myeloid leukemia patients with DNMT3A mutations.
    Xu Y; Sun Y; Shen H; Ding L; Yang Z; Qiu H; Sun A; Chen S; Wu D
    Am J Hematol; 2015 Nov; 90(11):992-7. PubMed ID: 26223865
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DNMT3A R882 Mutation with FLT3-ITD Positivity Is an Extremely Poor Prognostic Factor in Patients with Normal-Karyotype Acute Myeloid Leukemia after Allogeneic Hematopoietic Cell Transplantation.
    Ahn JS; Kim HJ; Kim YK; Lee SS; Jung SH; Yang DH; Lee JJ; Kim NY; Choi SH; Jung CW; Jang JH; Kim HJ; Moon JH; Sohn SK; Won JH; Kim SH; Kim DD
    Biol Blood Marrow Transplant; 2016 Jan; 22(1):61-70. PubMed ID: 26234722
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel impact of the DNMT3A R882H mutation on GSH metabolism in a K562 cell model established by TALENs.
    Yang L; Liu Y; Zhang N; Ding X; Zhang W; Shen K; Huang L; Zhou J; Cui S; Zhu Z; Hu Z; Xiao M
    Oncotarget; 2017 May; 8(18):30395-30409. PubMed ID: 28418922
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pre-transplant Quantitative Determination of NPM1 Mutation Significantly Predicts Outcome of AIlogeneic Hematopoietic Stem Cell Transplantation in Patients with Normal Karyotype AML in Complete Remission.
    Karas M; Steinerova K; Lysak D; Hrabetova M; Jungova A; Sramek J; Jindra P; Polivka J; Holubec L
    Anticancer Res; 2016 Oct; 36(10):5487-5498. PubMed ID: 27798920
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acute myeloid leukemia derived from lympho-myeloid clonal hematopoiesis.
    Thol F; Klesse S; Köhler L; Gabdoulline R; Kloos A; Liebich A; Wichmann M; Chaturvedi A; Fabisch J; Gaidzik VI; Paschka P; Bullinger L; Bug G; Serve H; Göhring G; Schlegelberger B; Lübbert M; Kirchner H; Wattad M; Kraemer D; Hertenstein B; Heil G; Fiedler W; Krauter J; Schlenk RF; Döhner K; Döhner H; Ganser A; Heuser M
    Leukemia; 2017 Jun; 31(6):1286-1295. PubMed ID: 27881874
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Persistence of DNMT3A R882 mutations during remission does not adversely affect outcomes of patients with acute myeloid leukaemia.
    Bhatnagar B; Eisfeld AK; Nicolet D; Mrózek K; Blachly JS; Orwick S; Lucas DM; Kohlschmidt J; Blum W; Kolitz JE; Stone RM; Bloomfield CD; Byrd JC
    Br J Haematol; 2016 Oct; 175(2):226-236. PubMed ID: 27476855
    [TBL] [Abstract][Full Text] [Related]  

  • 11. XPO1 inhibition displays anti-leukemia efficacy against DNMT3A-mutant acute myeloid leukemia via downregulating glutathione pathway.
    Cai X; Liu Y; Li H; Que Y; Xiao M; Wang Y; Wang X; Li D
    Ann Hematol; 2024 Jul; 103(7):2311-2322. PubMed ID: 38519605
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of nonleukemic cellular subcompartments reconstructs clonal evolution of acute myeloid leukemia and identifies therapy-resistant preleukemic clones.
    Saeed BR; Manta L; Raffel S; Pyl PT; Buss EC; Wang W; Eckstein V; Jauch A; Trumpp A; Huber W; Ho AD; Lutz C
    Int J Cancer; 2021 Jun; 148(11):2825-2838. PubMed ID: 33411954
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epigenetic Perturbations by Arg882-Mutated DNMT3A Potentiate Aberrant Stem Cell Gene-Expression Program and Acute Leukemia Development.
    Lu R; Wang P; Parton T; Zhou Y; Chrysovergis K; Rockowitz S; Chen WY; Abdel-Wahab O; Wade PA; Zheng D; Wang GG
    Cancer Cell; 2016 Jul; 30(1):92-107. PubMed ID: 27344947
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of DNMT3A variant allele frequency and double mutation on clinicopathologic features of patients with de novo AML.
    Narayanan D; Pozdnyakova O; Hasserjian RP; Patel SS; Weinberg OK
    Blood Adv; 2021 Jun; 5(11):2539-2549. PubMed ID: 34100902
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Functional role of DNMT3A mutation in acute myeloid leukemia].
    Koya J; Kurokawa M
    Rinsho Ketsueki; 2018; 59(5):602-610. PubMed ID: 29877252
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative examination of various PCR-based methods for DNMT3A and IDH1/2 mutations identification in acute myeloid leukemia.
    Berenstein R; Blau IW; Kar A; Cay R; Sindram A; Seide C; Blau O
    J Exp Clin Cancer Res; 2014 May; 33(1):44. PubMed ID: 24887327
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CpG Island Hypermethylation Mediated by DNMT3A Is a Consequence of AML Progression.
    Spencer DH; Russler-Germain DA; Ketkar S; Helton NM; Lamprecht TL; Fulton RS; Fronick CC; O'Laughlin M; Heath SE; Shinawi M; Westervelt P; Payton JE; Wartman LD; Welch JS; Wilson RK; Walter MJ; Link DC; DiPersio JF; Ley TJ
    Cell; 2017 Feb; 168(5):801-816.e13. PubMed ID: 28215704
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular evaluation of DNMT3A and IDH1/2 gene mutation: frequency, distribution pattern and associations with additional molecular markers in normal karyotype Indian acute myeloid leukemia patients.
    Ahmad F; Mohota R; Sanap S; Mandava S; Das BR
    Asian Pac J Cancer Prev; 2014; 15(3):1247-53. PubMed ID: 24606448
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic and Epigenetic Perturbations by DNMT3A-R882 Mutants Impaired Apoptosis through Augmentation of PRDX2 in Myeloid Leukemia Cells.
    Bera R; Chiu MC; Huang YJ; Liang DC; Lee YS; Shih LY
    Neoplasia; 2018 Nov; 20(11):1106-1120. PubMed ID: 30245403
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DNMT3A R882H mutation drives daunorubicin resistance in acute myeloid leukemia via regulating NRF2/NQO1 pathway.
    Chu X; Zhong L; Dan W; Wang X; Zhang Z; Liu Z; Lu Y; Shao X; Zhou Z; Chen S; Liu B
    Cell Commun Signal; 2022 Oct; 20(1):168. PubMed ID: 36303144
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.